While this drug combination was successful in providing a survival benefit to HF patients, it was also associated with an increased risk of angioedema owing to a significant buildup of bradykinin, no longer cleaved by neither ACE nor NEP [84]. The gene discussed is MME; the disease is hydrops fetalis.